Note: For those of you with an interest in developing bacterial vaccines, the results of Pfizer’s failed STRIVE S. aureus vaccine have now appeared in print along with an excellent editorial commentary. Deep sigh on this one — please see the updated prior newsletter for the links and the full story. This newsletter is part
Dear All, A recent paper by Hasegawa et al. and a multi-paper supplement, both in Clinical Infectious Diseases, combine to provide an interesting message. First, the paper by Hasegawa and colleagues. I’ve taken the title of this newsletter from an accompanying editorial by MacDougall who opens his commentary with “If there is one thing infectious
This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5. Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the
Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …
Dear All, A short one today! Please peruse both the funding opportunities and upcoming meetings just below my signature. Of special note: Building on the call in the recent biodefense-focused BAA from NIAID for diagnostic applications, JPIAMR is also looking for diagnostic applications (7 Mar deadline). Very interesting 2 Mar 2023 Duke-Margolis webinar entitled “Data Capture
Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check
Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space. As
Dear All, Wellcome Trust has renewed their support of AMR.Solutions and, with that, I’d like to share with you a survey about this newsletter. There are 3 questions and an optional comment box for you to write any additional thoughts you may have about this newsletter. I personally found last year’s survey to be highly
Please note that a very interesting Quality Improvement RFP has been added to the current funding opportunities listing with an application cut-off of 6 Oct … apologies for the late posting! Dear All, First up, CARB-X has at long last announced new funding rounds! As you’ll recall, CARB-X was recently funded for another 10 years by BARDA and Wellcome
Dear All, I have many times previously shared webinars from the excellent policy team at Duke-Margolis Center for Health Policy. Excitingly if you are in search of that type of role, they are now looking for a Policy Analyst who would be located in either Washington, DC or Durham, NC. Here is the verbatim job summary from